David M. Reese - May 2, 2023 Form 4 Insider Report for AMGEN INC (AMGN)

Role
EVP, Research and Development
Signature
/s/ David M. Reese
Stock symbol
AMGN
Transactions as of
May 2, 2023
Transactions value $
-$193,259
Form type
4
Date filed
5/4/2023, 08:32 PM
Previous filing
May 2, 2023
Next filing
May 9, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMGN Common Stock Award $0 +3.81K +7.38% $0.00 55.5K May 2, 2023 Direct F1
transaction AMGN Common Stock Tax liability -$193K -819 -1.47% $235.97 54.7K May 3, 2023 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMGN Nqso (Right to Buy) Award $0 +32.3K $0.00 32.3K May 2, 2023 Common Stock 32.3K $235.97 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/2/2025, 5/2/2026 and 5/2/2027, respectively.
F2 These shares include the following RSUs granted under the Company's equity plans: 2,325 RSUs which will vest in installments of 1,145 on 5/5/2023 and 1,180 on 5/5/2024; 2,685 RSUs which will vest in installments of 1,322 on 4/30/2024 and 1,363 on 4/30/2025; 3,897 RSUs which will vest in two installments of 1,286 on 5/2/2024 and 5/2/2025, and one installment of 1,325 on 5/2/2026; and 3,814 RSUs which will vest in installments of 1,258 on 5/2/2025, 1,259 on 5/2/2026, and 1,297 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
F3 These shares include 528 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
F4 These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/2/2025, 5/2/2026 and 5/2/2027, respectively.